Immune Checkpoint Inhibitors (ICIs) & Non-small-cell lung cancer (NSCLC)

ICI combinations and monotherapy showed improved clinical outcomes compared to chemotherapy. Adjusted analyses indicated no significant difference in outcomes between ICI monotherapy and ICI combinations.

In summary, the study highlights the growing adoption of ICI-based treatments in clinical practice and their association with improved outcomes for patients with CD274 (Programmed death-ligand 1 (PD-L1) positive metastatic Non-Small-Cell Lung Carcinoma (NSCLC)
Zhang et al. 2021w Immunotherapy 13(18): 1521-1533

Single-agent immune checkpoint inhibitors are now standard of care for advanced Non-Small-Cell Lung Carcinoma (NSCLC)
Melosky et al. 2020

Among previously treated NSCLC patients, four randomized Phase III studies have demonstrated an overall survival (OS) benefit for the three PD-L1 inhibitors (pembrolizumab, nivolumab and atezolizumab) compared with docetaxel monotherapy
Borghaei et al. 2015 N. Engl. J. Med. 373(17): 1627–1639
Brahmer et al. 2015 N. Engl. J. Med. 373(2): 123–135
Herbst et al. 2016 Lancet 387(10027): 1540–1550
Rittmeyer et al. 2017 Lancet 389(10066): 255–265

see also:
Akkermansia muciniphila & Anti-PD-1 antibodies / PD-1 inhibitors
Anti-PD-L1 Antibodies / PD-L1 Inhibitors & Non-small-cell lung cancer (NSCLC)
Akkermansia muciniphila & Immune Checkpoint Inhibitors (ICIs)
Avelumab & Non-Small-Cell Lung Carcinoma (NSCLC)
Atezolizumab + Nivolumab & Non-Small-Cell Lung Carcinoma (NSCLC)
Cancer Immunotherapy / Immuno-Oncology & Non-Small-Cell-Lung-Cancer (NSCLC)
Durvalumab & Non-small-cell lung cancer (NSCLC)
anti-PD-L1 & NSCLC
Immune Checkpoint Inhibitors (ICIs) & Non-Small-Cell Lung Carcinoma (NSCLC) (adenocarcinoma)
Ipilimumab + Nivolumab & Non-small-cell lung cancer (NSCLC)
Non-small-cell lung cancer (NSCLC) & Drugs/Treatments